< Back to Newsroom

A collaborative and exciting program that fosters the alliance between the AUA, BAUS and DGU, assisting in identifying future leaders within those organizations

REDWOOD SHORES, California, October 27, 2016 – PROCEPT BioRobotics, a medical device company developing a novel minimally invasive water ablation therapy to surgically treat prostate disease, has provided an educational grant in support of the 2017 American Urological Association Visiting Scholar program. This collaborative program supports the alliance between the BAUS (British Association of Urological Surgeons) and the DGU (Deutsche Gesellschaft für Urologie), and assists in identifying future leaders within those organizations.

This distinguished exchange program enables one practicing urologist from the BAUS and one practicing urologist from the DGU to visit a host institution in the United States for two weeks, and then attend the AUA Annual Meeting in Boston, Massachusetts, May 12-16, 2017. The selected scholar will observe urologic surgeries/procedures, attend clinics and staff activities, but will not perform surgery or hands- on patient care.

Supporting educational opportunities such as the AUA Visiting Scholar Program is an important component of PROCEPT’s mission to promote education and idea sharing throughout the international urological community.

Applications and required documents must be submitted online to the AUA by November 1, 2016. To learn more and apply, visit the AUA Visiting Scholar Program webpages:

  • 2017 AUA/BAUS Visiting Scholar Program
  • 2017 AUA/DGU Visiting Scholar Program

About PROCEPT BioRobotics
PROCEPT BioRobotics is a privately held medical device company that develops a novel minimally invasive technology to surgically treat prostate disease. The first product developed is the AQUABEAM® System, an intelligent image-guided robotic system delivering Aquablation, a personalized waterjet tissue resection modality. Under real-time image-based ultrasonic guidance, the AQUABEAM System enables surgical planning and mapping for improved decision making, and allows for a controlled resection of the prostate with a high-velocity saline stream. The combination of surgical mapping and controlled resection of the prostate is designed to offer predictable and reproducible outcomes which will enable quicker adoption and scaling of the technology. The company is privately held and headquartered in Redwood Shores, California. The AQUABEAM System is available for investigational use only in the United States and not currently available for sale in the United States.